Ftse Mib
33.795,75
0,15%
DAX
17.948,01
0,15%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
0,00
0,00%
Bitcoin
58.566,53
0,56%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mesoblast Limited (MESO) Mesoblast Limited (MESO) Notizie

Mesoblast Limited

MESO
7,21
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 12:35:35
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202403:05GLOBEAppendix 4c Quarterly Activity Report for Quarter Ended..
26/3/202414:25APSFDA Commentary Sends Biotech Soaring During Premarket Hours
26/3/202403:34GLOBEUnited States Food & Drug Administration (FDA) Notifies..
14/3/202400:30GLOBEMesoblast Successfully Completes Placement and Accelerated..
11/3/202400:54GLOBEUnited States Food & Drug Administration (FDA) Supports..
28/2/202423:57GLOBEMesoblast Reports Financial Results and Operational Update..
26/2/202413:00GLOBEMesoblast Financial Results and Corporate Update Webcast
15/2/202401:46GLOBEUnited States Food & Drug Administration (FDA) Grants..
01/2/202403:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202403:13GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended..
19/1/202401:28DJNMesoblast Gets FDA's Special Pediatric Designation for..
19/1/202400:36GLOBEUnited States Food & Drug Administration (FDA) Grants..
16/1/202412:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202403:57EDGAR2Form F-6 POS - Post-effective amendments for immediately..
22/12/202323:13EDGAR2Form F-6 POS - Post-effective amendments for immediately..
27/11/202300:56GLOBEMesoblast Files for Orphan Drug and Pediatric Rare Disease..
22/11/202319:35APSBiotech Shares Soar Following Major Announcement
22/11/202300:32GLOBEMesoblast Partners With Blood and Marrow Transplant Clinical..
31/10/202301:04GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended..
26/9/202312:18GLOBEJane Bell AM Appointed Chair of Mesoblast Audit and Risk..
21/9/202309:30GLOBEKey Outcomes From FDA Type A Meeting and Mesoblast Next..
06/9/202312:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/8/202301:07GLOBEMesoblast Reports Financial Results and Operational Update..
29/8/202313:00GLOBEMesoblast Financial Results and Corporate Update Webcast
04/8/202315:03DJNMesoblast ADSs Plunge Premarket on Latest FDA Rejection
04/8/202302:10GLOBEMesoblast Receives Complete Response From U.S. Food and Drug..
31/7/202302:31GLOBEAppendix 4C Quarterly Activity Report for Quarter Ended June..
05/6/202302:21GLOBEMesoblast Director Philip R. Krause, M.D., Appointed to..
26/5/202301:28GLOBEMesoblast Reports Operational and Financial Highlights for..
24/5/202313:00GLOBEMesoblast Financial Results and Corporate Update Webcast
Apertura: Min: Max:
Chiusura: 7,21

La tua Cronologia

NASDAQ
MESO
Mesoblast
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network